Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial

Objective. Until recently, advanced medullary thyroid cancer (MTC) had few treatment options except surgery. The mTOR inhibitor everolimus has shown encouraging results in neuroendocrine tumors. As part of a prospective phase II study, we analyzed the safety and efficacy of everolimus in advanced MT...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, T. C., de Wit, D., Links, T. P., van Erp, N. P., van der Hoeven, J. J. M., Gelderblom, H., van Wezel, T., van Eijk, R., Morreau, H., Guchelaar, H. J., Kapiteijn, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532868/
https://www.ncbi.nlm.nih.gov/pubmed/26294908
http://dx.doi.org/10.1155/2015/348124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532868/
https://www.ncbi.nlm.nih.gov/pubmed/26294908
http://dx.doi.org/10.1155/2015/348124

Ejemplares similares